His new environment is a challenge, but Christian Knobloch, new vice president of business development at EuroProteome, is enjoying the change of scenery. Not only does he get to enjoy the up-and-coming area of Hennigsdorf near Berlin, but he also gets to move from a 1,000-person company to a faster-paced one where the head count is about 25.
EuroProteome uses mass spec and other proteomics technologies as well as bioinformatics tools to design diagnostics and therapeutics for epithelial cancers. Knobloch’s role is to seek out more business opportunities for what the company’s been doing.
He left his former job at Knoll, the pharmaceutical arm of BASF, late last year to join the venture-financed startup at the beginning of this year. Among his plans for EuroProteome: “to increase [the staff] to about 50 to 60,” he says. An IPO may also be in the offing, but there are no set plans for it. “Like with every startup, an IPO is the mid- and long-term goal.”
The startup atmosphere is agreeing with Knobloch. He explains that he likes the idea of achieving success not just by continuing to sell an old product but by creating a whole new business.
Though he has a background in oncology and immunology, it’s actually the business that’s most intriguing to Knobloch. “It’s on the edge between science and commerce — that’s an area I just find very interesting in general.” And unlike larger organizations where he’d be more narrowly focused, “the scope of responsibility I have here is truly a global one. I can work internationally,” he says.
— Meredith Salisbury